J Gastroenterol Hepatol Endosc | Volume 3, Issue 3 | Short Communication | Open Access
Akif Altinbas1*, Baris Yilmaz2, Mustafa Goktas3, Sahin Coban4 and Melih O Babaoglu5
1Department of Gastroenterology, Diskapı Yildirim Beyazit Education and Research Hospital, Gastroenterology Clinic, Turkey
2Department of Gastroenterology, Diskapı Yildirim Beyazit Education and Research Hospital, Gastroenterology Clinic, Turkey
3Department of Pharmacology, Hacettepe University, Turkey
4Department of Gastroenterology, Diskapı Yildirim Beyazit Education and Research Hospital, Gastroenterology Clinic, Turkey
5Department of Pharmacology, Hacettepe University, Turkey
*Correspondance to: Akif Altinbas
Fulltext PDFBackground: The CYP2C19*17 allele has been shown to be related to faster Pantoprazole metabolism, whereas the *2 and *3 alleles are related to poor metabolism. We aimed to investigate the effect of CYP2C19 polymorphisms on treatment of gastro-esophageal reflux disease.
Materials and Methods: Patients admitted to the Endoscopy unit and diagnosed with grade A or B esophagitis were included in the study. Patients were enrolled in two groups: Group 1 (N: 50) consisted of patients taking 40 mg Pantoprazole, and Group 2 (N: 41) those taking 80 mg per day. After 8 weeks of treatment, a second endoscopic procedure was performed to evaluate healing of the esophagitis. In addition, CYP2C19 genotyping for *2, *3 and *17 was performed for all of the patients.
Results: The healing rates of esophagitis were 82% and 80.5% in Groups 1 and 2, respectively. All of the patients with the *2*2 polymorphism were cured, in contrast only 66.7% of those with the *17*17 polymorphism healed.
Conclusion: In this preliminary study, the healing rates of esophagitis were comparable to results of reported studies in the literature. Being slow metabolizer may be a favorable effect on GERD treatment outcome.
Gastroesophageal reflux disease; CYP2C19 polymorphism; Pantoprazole
Altinbas A, Yilmaz B, Goktas M, Coban S, Babaoglu MO. Impact of CYP2C19 Gene Polymorphism on Gastroesophageal Reflux Disease. J Gastroenterol Hepatol Endosc. 2018;3(3):1048.